Yun Bin Lee

Yun Bin Lee

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Journal of Hepatology
Verified
Journal Article
Closed access
HKHwi Young Kim
Hwi Young Kim
PLPietro Lampertico
Pietro Lampertico
JNJoon Yeul Nam
Joon Yeul Nam
HLHyung-Chul Lee
Hyung-Chul Lee
SKSeung Up Kim
Seung Up Kim
JLJeong-Hoon Lee
Jeong-Hoon Lee

1 June 2019 in Journal of Hepatology
Verified
Journal Article
Closed access
EPEun-Sook Park
Eun-Sook Park
ALAh Ram Lee
Ah Ram Lee
DKDoo Hyun Kim
Doo Hyun Kim
JLJeong-Hoon Lee
Jeong-Hoon Lee
JYJeong-Ju Yoo
Jeong-Ju Yoo
KKKyun-Hwan Kim
Kyun-Hwan Kim

25 March 2019 in Clinical and Molecular Hepatology
Verified
Journal Article
Open access
PDF file
YLYun Bin Lee
Yun Bin Lee
YHYeonjung Ha
Yeonjung Ha
YCYoung Eun Chon
Young Eun Chon
MKMi Na Kim
Mi Na Kim
JLJoo Ho Lee
Joo Ho Lee
SHSeong Gyu Hwang
Seong Gyu Hwang
Nonalcoholic fatty liver disease (NAFLD) is becoming a worldwide epidemic, and is frequently found in patients with chronic hepatitis B (CHB). We investigated the impact of histologically proven hepatic steatosis on the risk for hepatocellular carcinoma (HCC) in CHB patients without excessive alcohol intake. Consecutive CHB patients who underwent liver biopsy from January 2007 to December 2015 were included. The association between hepatic steatosis (≥ 5%) and subsequent HCC risk was analyzed. Inverse probability weighting (IPW) using the propensity score was applied to adjust for differences in patient characteristics, including metabolic factors. Fatty liver was histologically proven in 70 patients (21.8%) among a total of 321 patients. During the median (interquartile range) follow-up of 5.3 (2.9-8.3) years, 17 of 321 patients (5.3%) developed HCC: 8 of 70 patients (11.4%) with fatty liver and 9 of 251 patients (3.6%) without fatty liver. The five-year cumulative incidences of HCC among patients without and with fatty liver were 1.9% and 8.2%, respectively (P=0.004). Coexisting fatty liver was associated with a higher risk for HCC (adjusted hazards ratio [HR], 3.005; 95% confidence interval [CI], 1.122-8.051; P=0.03). After balancing with IPW, HCC incidences were not significantly different between the groups (P=0.19), and the association between fatty liver and HCC was not significant (adjusted HR, 1.709; 95% CI, 0.404-7.228; P=0.47). Superimposed NAFLD was associated with a higher HCC risk in CHB patients. However, the association between steatosis per se and HCC risk was not evident after adjustment for metabolic factors.

1 April 2012 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
JLJoo Hyun Lim
Joo Hyun Lim
SKSang Gyun Kim
Sang Gyun Kim
JKJi Won Kim
Ji Won Kim
YCYoon Jin Choi
Yoon Jin Choi
JKJieun Kwon
Jieun Kwon
ISIn Sung Song
In Sung Song

24 August 2017 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
SKSeong Hee Kang
Seong Hee Kang
YLYun Bin Lee
Yun Bin Lee
JLJeong-Hoon Lee
Jeong-Hoon Lee
JNJ. Y. Nam
J. Y. Nam
YCY. Chang
Y. Chang
JYJ.‐H. Yoon
J.‐H. Yoon

17 May 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ECEun Ju Cho
Eun Ju Cho
SLSangseob Leem
Sangseob Leem
SKSun Ah Kim
Sun Ah Kim
Jinho YangJinho Yang
Jinho Yang
YLYun Bin Lee
Yun Bin Lee
Taesung ParkTaesung Park
Taesung Park
Circulating microbial dysbiosis is associated with chronic liver disease including nonalcoholic steatohepatitis and alcoholic liver disease. In this study, we evaluated whether disease-specific alterations of circulating microbiome are present in patients with cirrhosis and hepatocellular carcinoma (HCC), and their potential as diagnostic biomarkers for HCC. We performed cross-sectional metagenomic analyses of serum samples from 79 patients with HCC, 83 with cirrhosis, and 201 matching healthy controls, and validated the results in the same number of subjects. Serum bacterial DNA was analyzed using high-throughput pyrosequencing after amplification of the V3–V4 hypervariable regions of 16S rDNA. Blood microbial diversity was significantly reduced in HCC, compared with cirrhosis and control. There were significant differences in the relative abundances of several bacterial taxa that correlate with the presence of HCC, thus defining a specific blood microbiome-derived metagenomic signature of HCC. We identified 5 microbial gene markers-based model which distinguished HCC from controls with an area under the receiver-operating curve (AUC) of 0.879 and a balanced accuracy of 81.6%. In the validation, this model accurately distinguished HCC with an AUC of 0.875 and an accuracy of 79.8%. In conclusion, circulating microbiome-based signatures may be potential biomarkers for the detection HCC.